End-of-day quote
Korea S.E.
03:30:00 22/05/2024 am IST
|
5-day change
|
1st Jan Change
|
13,960
KRW
|
+1.16%
|
|
-6.75%
|
+298.86%
|
Fiscal Period: December |
2023
|
---|
Capitalization
1 |
34,879
|
Enterprise Value (EV)
1 |
-1,08,157
|
P/E ratio
|
0.39
x
|
Yield
|
57.1%
|
Capitalization / Revenue
|
0.1
x
|
EV / Revenue
|
-0.3
x
|
EV / EBITDA
|
-0.73
x
|
EV / FCF
|
-1.15
x
|
FCF Yield
|
-86.8%
|
Price to Book
|
0.15
x
|
Nbr of stocks (in thousands)
|
9,965
|
Reference price
2 |
3,500
|
Announcement Date
|
21/03/24
|
Fiscal Period: December |
2023
|
---|
Net sales
1 |
3,55,847
|
EBITDA
1 |
1,48,675
|
EBIT
1 |
1,42,339
|
Operating Margin
|
40%
|
Earnings before Tax (EBT)
1 |
1,52,435
|
Net income
1 |
1,16,436
|
Net margin
|
32.72%
|
EPS
2 |
8,921
|
Free Cash Flow
1 |
93,874
|
FCF margin
|
26.38%
|
FCF Conversion (EBITDA)
|
63.14%
|
FCF Conversion (Net income)
|
80.62%
|
Dividend per Share
2 |
2,000
|
Announcement Date
|
21/03/24
|
Fiscal Period: December |
2023
|
---|
Net Debt
1 |
-
|
Net Cash position
1 |
1,43,036
|
Leverage (Debt/EBITDA)
|
-
|
Free Cash Flow
1 |
93,874
|
ROE (net income / shareholders' equity)
|
47.3%
|
ROA (Net income/ Total Assets)
|
31.2%
|
Assets
1 |
3,72,839
|
Book Value Per Share
2 |
23,103
|
Cash Flow per Share
2 |
8,642
|
Capex
1 |
35,703
|
Capex / Sales
|
10.03%
|
Announcement Date
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +298.86% | 143M | | -6.16% | 12.09B | | -3.26% | 8.21B | | +6.61% | 5.74B | | +31.20% | 5.64B | | -9.05% | 4.16B | | -56.99% | 2.88B | | +11.87% | 2.69B | | -5.34% | 2.33B | | +25.34% | 2.17B |
Diagnostic & Testing Substances
|